Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Dose-ranging, Multicenter Study to Determine the Antibody Response to G17DT and Its Safety and Tolerability in the Treatment of Patients With Gastric Cancer

NCT02521649 is registered in ClinicalTrials.gov with Cancer Advances Inc. as lead sponsor.

NCT NCT02521649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02521649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Dose-ranging, Multicenter Study to Determine the Antibody Response to G17DT and Its Safety and Tolerability in the Treatment of Patients With Gastric Cancer
Lead sponsor
Cancer Advances Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 1998
Completion date
January 31, 2001
Enrollment
52 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer